Company Overview

Incorporated in 1989, Vaishali Pharma Ltd is an esteemed pharmaceutical organization that has evolved from a PAN-India raw material trader into a diversified pharmaceutical powerhouse. With headquarters located in Mumbai's economic hub, the company went public and got listed on the NSE on 15th January 2020, establishing itself as a significant player in India's healthcare sector.

Vaishali Pharma Limited manufactures and distributes pharmaceutical products, offering herbal preparations, nutraceuticals, and surgical products for the prevention, diagnosis, and treatment of diseases, disorders, and injuries. The company operates with a strong foundation built on quality manufacturing and regulatory compliance, serving both domestic and international markets with a comprehensive portfolio of healthcare solutions.

Business Segments and Product Portfolio

Vaishali Pharma operates across multiple therapeutic segments with a diverse product range. The company offers a comprehensive portfolio encompassing Active Pharmaceutical Ingredients (APIs), Finished Formulations, Surgical, Herbals, Veterinary products, Nutraceuticals, Oncology, and the newly added Contrast Media. The company produces various dosage forms encompassing a vast range of therapeutic categories, mainly focusing on antibiotics, antidiabetic, and antimalarial products.

In the API segment, Vaishali offers antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The formulation products include antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, cardiac, anti-diabetic, anti-inflammatory/analgesic/anti-pyretic, topical steroids/corticosteroids, anti-fungal, vitamins, and other formulations.

Global Presence and Market Reach

The company has been successfully delivering products and expanding its business for thirty years with more than 300 clientele reaching out globally, emerging as one of the fastest-growing organizations in the pharmaceutical industry across the globe. With offices established in Kenya and Vietnam (Ho Chi Minh City), the company continues widening its reach overseas. Vaishali has more than 250+ brands registered in various countries and exports to 20+ countries.

The company provides 1500+ products and 250+ brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations. This extensive global footprint demonstrates the company's commitment to making quality healthcare accessible worldwide while maintaining compliance with international regulatory standards.

Quality Standards and Certifications

The legitimacy of Vaishali's product quality has been certified by ISO 9001:2008 certification for Quality Management from BM Trada UKAS. The company complies with all regulatory requirements of different countries with their respective rules, regulations, and documentation. Products are manufactured with stringent quality procedures, providing the best results, and are strong and hard to withstand any mechanical shock during manufacturing, packing, shipping, dispensing, and use, releasing content in a predictable and reproducible manner, providing reasonable physical and chemical stability.

The 'Vaishalians Code of Conduct' provides a strong framework for business ethics by balancing corporate values through Integrity, Customer-centric approach, Innovation, Passion, Productivity, and Adaptability. This commitment to quality and ethics has been instrumental in building trust with healthcare providers and patients across multiple markets.

Financial Performance and Market Position

As of the latest available data, Vaishali Pharma Ltd has a market capitalization of ₹127.13 Cr as of 27th June 2025. For the full year ended March 2025, net profit rose 13.89% to Rs 0.82 crore compared to Rs 0.72 crore in the previous year, while sales rose 14.78% to Rs 99.03 crore against Rs 86.28 crore in FY2024.

Key Financial Metrics:

- Revenue (FY2025): ₹99.03 Crore

- Net Profit (FY2025): ₹0.82 Crore

- Market Capitalization: ₹127.13 Crore (as of June 27, 2025)

- Promoter Holding: ~26.3% (25.58% reported)

- P/E Ratio: 156.95

- P/B Ratio: 2.97

The promoters of Vaishali Pharma Ltd are Atul Arvindbhai Vasani and Jagruti Atul Vasani, who collectively own 25.58 percent of the total equity. As per Value Research classification, it is classified as a Small Cap company.

Strategic Focus Areas

The company has demonstrated particular strength in diabetes management solutions. Vaishali Pharma is empowering health through diabetes management medications and making a difference in the fight against diabetes. Beyond pharmaceuticals, the company offers comprehensive support to business partners, including regulatory support, contract manufacturing services, marketing collateral, and personalized guidance.

The company thrives on collaboration and working across the world, working closely with B2B partners to co-create solutions that address unique market needs. This collaborative approach has enabled Vaishali to build strong partnerships across its global network while maintaining focus on innovation and quality delivery.